晚期非小细胞肺癌老年与年轻患者治疗失败时间及相关结局比较(Alliance A151711)
该研究汇总三项一线化疗试验(CALGB 9730、30203、30801)共1006例晚期NSCLC患者,比较≥65岁与<65岁患者的治疗失败时间(TTF)。结果显示两组中位TTF无统计学显著差异,但早期终止化疗的原因不同:老年患者因癌症进展停药较少,因毒性或患者选择停药较多;≥70岁亚组TTF亦无差异。
要点
- 老年与年轻患者中位TTF无统计学显著差异,调整体能状态后结论一致。
- 老年患者因癌症进展停药比例较低(41% vs 55%),因毒性或患者选择停药比例较高。
- 老年患者3级及以上不良事件发生率更高(86% vs 79%),但生存无统计学显著差异。
核心结论
- 老年与年轻晚期NSCLC患者一线化疗的TTF相当,但早期终止化疗的原因存在年龄相关差异且部分可干预。
研究设计与样本
- 汇总三项一线化疗试验(CALGB 9730、30203、30801)的1006例晚期NSCLC患者进行回顾性分析。
- 460例(46%)患者年龄≥65岁,主要终点为TTF,并比较早期终止化疗原因、3级及以上不良事件及总生存。
主要发现
- ≥65岁患者中位TTF为2.9个月(95%CI 2.7-3.2),年轻患者为3个月(95%CI 2.9-3.5),调整体能状态及按试验化疗分层后无统计学显著差异。
- 老年患者因癌症进展停药比例为41%,年轻患者为55%;老年患者因毒性停药比例为16%、因患者选择停药比例为15%,年轻患者分别为13%和6%(多变量P=0.004)。
- 老年患者3级及以上不良事件发生率为86%,年轻患者为79%,生存无统计学显著差异。
- 以70岁为界分析,TTF无差异,老年患者因癌症进展早期停药呈较低趋势,生存略短。
关键数值与推荐
- 早期终止化疗原因在年龄组间差异有统计学意义(多变量P=0.004)。
临床怎么用
- 老年晚期NSCLC患者一线化疗的TTF与年轻患者相当,不应仅因年龄限制化疗。
- 对老年患者需更关注毒性和患者意愿导致的早期停药,加强毒性管理和共享决策。
局限性
- 为汇总三项试验的回顾性分析,化疗方案与年代可能影响结果外推。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Time-to-treatment-failure (TTF) is the interval from chemotherapy initiation to premature discontinuation. We evaluated TTF based on age. METHODS: Pooled analyses were conducted with first-line chemotherapy trials for advanced NSCLC (CALGB 9730, 30203, and 30801). Comparisons among patients who were 65 years and older and 70 years and older were performed for TTF (primary endpoint), reasons for early chemotherapy cessation, grade 3+ adverse events, and overall survival. RESULTS: Among 1006 patients, 460 (46%) were older than 65 years of age. One hundred forty-five older patients (32% of this age cohort) completed all six planned chemotherapy cycles as did 170 (32%) younger patients. Median TTF was 2.9 months (95% confidence interval: 2.7- 3.2) in older patients and 3 months (95% confidence interval: 2.9-3.5) in younger patients; adjustment for performance status and stratification by chemotherapy by trial yielded no statistically significant age-based difference in TTF. However, reasons for early chemotherapy cessation differed between age groups (multivariate p = 0.004). Older patients were less likely to discontinue from cancer progression (41% versus 55%) and more likely from toxicity or patient choice (16% and 15%, respectively) compared to younger patients (13% and 6%, respectively). Older patients were more likely to experience grade 3+ adverse events (86% versus 79%) with no statistically significant difference in survival. An age cutpoint of 70+ years showed no difference in TTF, a lower trend of early cessation due to cancer progression, and somewhat shorter older patient survival. CONCLUSIONS: TTF was comparable between older and younger patients; but different, age-based, and potentially modifiable reasons account for it.
引用
- Gajra A, Zemla TJ, Jatoi A, et al. Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711). J Thorac Oncol. 2018. PMID: 29608967. doi:10.1016/j.jtho.2018.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。